David Tai
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 28
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 15
- Pancreatic and Hepatic Oncology Research 12
- Colorectal Cancer Treatments and Studies 8
- Immunology top 10%
- Infectious Diseases top 10%
- Gastroenterology top 10%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 8
-
- Fibroblast Growth Factor Research 7
-
- Gastric Cancer Management and Outcomes 7
-
- Cancer Genomics and Diagnostics 6
- Co-authors
- Su Pin ChooShue‐Shian ChiouYun‐Fan LiawChi‐Sin ChangchienValerie ChewJoycelyn Jie Xin LeeConnie YipYun Hua Lee
- Cited by
- HepatologyOncologyImmunology
- Journals
- Annals of Oncology (12 papers)Journal of Clinical Oncology (10 papers)Liver Cancer (5 papers)
- Partner nations
- SingaporeUnited StatesSouth Korea
In The Last Decade
David Tai
72 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Hepatology 522
- Oncology 737
- Immunology 254
- Infectious Diseases 220
- Gastroenterology 61
Countries citing papers authored by David Tai
This map shows the geographic impact of David Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tai more than expected).
Fields of papers citing papers by David Tai
This network shows the impact of papers produced by David Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tai. The network helps show where David Tai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Tai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 8 | |
| 3 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.breakdown → | 2024 | 75 |
| 4 | 2024 | 29 | |
| 5 | 2023 | 13 | |
| 6 | 2023 | 34 | |
| 7 | 2023 | 0 | |
| 8 | 2023 | 1 | |
| 9 | 2022 | 4 | |
| 10 | Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumorsbreakdown → | 2021 | 257 |
| 11 | 2021 | 68 | |
| 12 | 2021 | 11 | |
| 13 | 2020 | 3 | |
| 14 | 2020 | 100 | |
| 15 | 2018 | 8 | |
| 16 | 2017 | 30 | |
| 17 | 2015 | 118 | |
| 18 | 2015 | 29 | |
| 19 | 2012 | 45 | |
| 20 | 2011 | 79 |
About David Tai
David Tai is a scholar working on Hepatology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Gastroenterology, having authored 76 papers that have together received 1.8k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Cancer Immunotherapy and Biomarkers (15 papers), Pancreatic and Hepatic Oncology Research (12 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), Colorectal Cancer Treatments and Studies (8 papers), Fibroblast Growth Factor Research (7 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Hepatology (522 citations), Oncology (737 citations), Immunology (254 citations), Infectious Diseases (220 citations) and Gastroenterology (61 citations). David Tai has collaborated with scholars based in Singapore, United States and South Korea. Frequent co-authors include Su Pin Choo, Shue‐Shian Chiou, Yun‐Fan Liaw, Chi‐Sin Changchien, Valerie Chew, Joycelyn Jie Xin Lee, Connie Yip, Yun Hua Lee, Armando Santoro and Pierce K. H. Chow. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Liver Cancer, Surgery and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.